Skin Care Research is enrolling participants for a Recurrent Cutaneous Squamous Cell Carcinoma clinical trial in Hollywood, FL. Qualified participants will receive all study-related care provided by board-certified dermatologists at one of our partnered clinics. All Skin Care Research studies are in compliance with FDA guidelines and uphold the highest clinical standards.
To Qualify:
- Must be 18 years and older
- Be willing to travel to Hollywood, FL (transportation may be provided)
To learn more, fill out a form on this page or call 561-948-3116
NO COST. NO INSURANCE. MAY QUALIFY FOR COMPENSATION.
What is Recurrent Cutaneous Squamous Cell Carcinoma?
Recurrent cutaneous squamous cell carcinoma (recurrent cSCC) is a type of skin cancer that returns after it has already been treated, either in the same area of skin or nearby. Cutaneous squamous cell carcinoma develops from squamous cells in the outer layer of the skin and is often linked to long-term sun exposure, though it can also occur in areas of prior injury or inflammation. When cSCC recurs, it may come back as a new growth, a non-healing sore, or a thickened/scaly patch, and in some cases it can become more aggressive than the original tumor. Because recurrent cSCC can have a higher risk of spreading to deeper tissues or nearby lymph nodes, it’s important to monitor closely and treat promptly under the care of a dermatologist or oncology specialist.
About Skin Care Research
As a clinical research center with over 25 years of experience in the execution of dermatological and cosmetic clinical trials, Skin Care Research has conducted hundreds of successful research studies for trusted brands including Abbvie, Eli Lilly, Galderma, Pfizer Inc, and more. Our research staff and board-certified dermatologists are highly trained and experienced in conducting FDA approved clinical trials.
To learn more about our enrolling studies, including time commitment, participant responsibilities, and other things you should expect, fill out the form or give us a call at 561-948-3116.
